Krystal Biotech, Inc. (NASDAQ:KRYS) Stock Position Lowered by Jennison Associates LLC

Jennison Associates LLC reduced its position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 26.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 303,521 shares of the company's stock after selling 106,536 shares during the period. Jennison Associates LLC owned 1.06% of Krystal Biotech worth $47,550,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Bank of Montreal Can purchased a new position in Krystal Biotech during the 2nd quarter worth approximately $540,000. Squarepoint Ops LLC acquired a new stake in Krystal Biotech during the 2nd quarter worth $442,000. AQR Capital Management LLC boosted its stake in Krystal Biotech by 25.7% during the 2nd quarter. AQR Capital Management LLC now owns 7,587 shares of the company's stock worth $1,393,000 after purchasing an additional 1,551 shares during the last quarter. Algert Global LLC purchased a new position in shares of Krystal Biotech during the 2nd quarter worth $340,000. Finally, Creative Planning raised its holdings in shares of Krystal Biotech by 21.6% during the 2nd quarter. Creative Planning now owns 3,484 shares of the company's stock worth $640,000 after acquiring an additional 618 shares during the period. 86.29% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Stock Performance

Shares of NASDAQ:KRYS traded down $6.19 during mid-day trading on Friday, hitting $154.87. 296,332 shares of the company traded hands, compared to its average volume of 236,087. Krystal Biotech, Inc. has a 52-week low of $107.50 and a 52-week high of $219.34. The firm's 50 day simple moving average is $161.98 and its 200 day simple moving average is $178.09. The firm has a market cap of $4.45 billion, a P/E ratio of 87.50 and a beta of 0.84.

Analyst Ratings Changes

Several analysts recently issued reports on KRYS shares. Citigroup boosted their price objective on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a "neutral" rating in a report on Tuesday, November 5th. HC Wainwright reaffirmed a "buy" rating and issued a $221.00 price target on shares of Krystal Biotech in a report on Wednesday, December 18th. Finally, Chardan Capital reiterated a "buy" rating and issued a $212.00 price objective on shares of Krystal Biotech in a research report on Wednesday, December 18th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Krystal Biotech has a consensus rating of "Buy" and a consensus price target of $206.67.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the transaction, the insider now owns 1,475,882 shares in the company, valued at $243,195,835.96. The trade was a 1.67 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 14.10% of the company's stock.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).